|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Protein therapies for the treatment of immune-mediated disorders. |
|
| Management |
| Niclas Stiernholm, PhD, Chief Executive Officer; Bob Uger, PhD, Vice President, Research and Development; Craig Binnie, PhD, Director, Drug Development; Scott Duncan, BSc, Director, Patents and Licensing |
| |
|
|
| |
|
| Keywords |
| immunology, immune-mediated disorder, monoclonal antibodies, secreted proteins, peptides, AllergyImmunology |
|
|
|
| Description |
|
Trillium Therapeutics Inc. specializes in the discovery and development of innovative therapies for the treatment of immune-mediated disorders. |
|
| Products / Services |
TTI has three scientific programs containing six product opportunities at various stages of preclinical testing. One program focuses on the immunoregulatory protein CD200 and its receptor, a second is based upon the activating Fc receptor FcgRIIa (CD32a) and the third involves the use of a growth factor in the treatment of gastrointestinal inflammation and damage. The company has numerous research collaborations that provide access to world-class laboratories and a series of discovery projects.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members